AFP and liver cancer: Patients had advanced disease of mostly Barcelona Clinic Liver Cancer Stage C (7, 87.5%), and a significant proportion had portal vein involvement (3, 37.5%) and AFP ≥400 ng/ml (6, 75%), and had received prior sorafenib treatment (5, 62.5%).